
|Videos|July 16, 2020
Case of A 68-Year-Old Man With Gastrointestinal Stromal Tumor
Author(s)Neeta Somaiah, MD
Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.
Advertisement
Case:
A 68-Year-Old Man With Gastrointestinal Stromal Tumor
Initial presentation
- A 68-year-old man complains of a 4-month history of decreased appetite, vague abdominal discomfort and a sensation of fullness
- PMH: DM, medically controlled; colonoscopy at age 50 was unremarkable; no family history of cancer
- PE: abdominal pain on deep palpation; otherwise unremarkable
Clinical workup
- Labs: Hb 10.5 g/dL, plt 105 x 109/L; other lab values WNL
- Endoscopy: showeda submucosal ~6 cm mass with ulceration
- EUS: irregular borders on extraluminal surfaces with marginal halo and hyperechogenic spots
- FNA biopsy: mitotic activity showed >5 mitoses/50 HPFs
- Mutational testing: WT-GIST
- Abdominal/pelvic CT confirmed a 6.2 cm lesion with indistinct margins in the body of the stomach
- MRI showed 3 small hepatic lesions consistent with metastases
- Stage IV; ECOG 0
Treatment
- He was started on imatinib 400 mg PO qDay, continued for 24 months until he complained of increased abdominal pain and an additional 8-lb weight loss
- ECOG 1; Imatinib was discontinued
- Treatment initiated with sunitinib 50 mg PO qDay for 4 weeks, with a 2-week drug-free interval
- Treatment was well tolerated for 3 cycles when he developed nausea and vomiting; dose reduced to 25 mg PO qDay without resolution of AEs; sunitinib was discontinued
- Regorafenib 160 mg (four 40 mg tablets) PO qDay for the first 21 days of each 28-day cycle was started, poorly tolerated
- Repeat lab work showed: Hb 8.9, AST 65 IU/I; regorafenib was discontinued
- The patient was started on ripretinib 150 mg PO qDay
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































